Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on March 9, 2017
LEXINGTON, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2016 financial results on Thursday, March 9, 2017, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST, to review its various pipeline programs, including CUDC-907, a dual HDAC/ PI3K inhibitor, CA-170, an oral small molecule antagonist of PD-L1/VISTA and other molecules under collaboration with Aurigene, and its partnered program, Erivedge® (vismodegib). The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2016.
To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EST. The conference ID number is 84640331. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.
About Curis, Inc.
For more information, visit Curis' website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 email@example.com Media Contact: David Schull Russo Partners 212-845-4271 firstname.lastname@example.org